Inflammation in sporadic colorectal cancer

Archives of Iranian Medicine

Volumn 15, Issue 3, 2012, Pages 166-170

  Moossavi, Shirin ^a   Bishehsari, Faraz ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Inflammation; Sporadic colorectal cancer; Tumorigenesis

Indexed keywords

CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PROSTAGLANDIN E2; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ADENOCARCINOMA; APC GENE; CARCINOGENESIS; CD4+ T LYMPHOCYTE; COLORECTAL CANCER; DISEASE ASSOCIATION; DYSPLASIA; ENTERITIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; IMMUNE DEFICIENCY; INFLAMMATION; INTESTINE FLORA; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SPORADIC COLORECTAL CANCER; TUMOR GENE;

CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES;

EID: 84857972715     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. Lyon, France: International Agency for Research on Cancer. Retrieved March 1, 2011. Available from: URL: http://globocan.iarc.fr.
2. Fearon EF, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990; 61: 759-767.
3. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011; 6: 479-507.
4. Oguma K, Oshima H, Aoki M, Uchio R, Naka K, Nakamura S, et al. Activated macrophages promote Wnt signalling through tumour necrosis factor-α in gastric tumour cells. EMBO J. 2008; 27: 1671-1681.
5. Kaler P, Godasi BN, Augenlicht L, Klampfer L. The NF-κB/AKTdependent induction of Wnt signaling in colon cancer cells by macrophages and IL-1β. Cancer Microenviron. 2009; 2: 69-80.
6. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gsaxin-β-catenin signaling axis. Science. 2005; 310: 1504-1510.
7. Umar S. Intestinal stem cells. Curr Gastroenterol Rep. 2010; 12: 340-348.
8. Asquith M, Powrie F. An innately dangerous balancing act: Intestinal homeostasis, inflammation, and colitis-associated cancer. J Exp Med. 2010; 207: 1573-1577.
9. Chichlowski M, Hale LP. Bacterial-mucosal interactions in inflammatory bowel disease: an alliance gone bad. Am J Physiol Gastrointest Liver Physiol. 2008; 295: G1139-G1149.
10. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001; 91: 854-862.
11. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2000; 14: 145-153.
12. Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther. 2006; 23: 1097-1104.
13. Gyde SN, Prior P, Allan RN, Stevens A, Jewell DP, Truelove SC, et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut. 1988; 29: 206-217.
14. Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007; 133: 1099-1105.
15. McCart AE, Vickaryous NK, Silver A. Apc mice: Models, modifiers, and mutants. Pathol Res Pract. 2008; 204: 479-490.
16. Min/+mice: inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms. Int J Cancer. 2006; 118: 25-34.
17. Min/+ mice. Cancer Res. 2006; 66: 57-61.
18. Min/+ mice. Cancer Res. 2005; 65: 3998-4004.
19. Nascimbeni R, Di Fabio F, Di Betta E, Mariani P, Fisogni S, Villanacci V. Morphology of colorectal lymphoid aggregates in cancer, diverticular and inflammatory bowel diseases. Mod Pathol. 2005; 18: 681-685.
20. Min/+ mice. Int J Exp Path. 2006; 87: 227-236.
21. Chae WJ, Gibsona TF, Zelterman D, Hao L, Henegariu O, Bothwella ALM. Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proc Natl Acad Sci USA. 2010; 107: 5540-5544.
22. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer. 2007; 121: 2381-2386.
23. Lonkar P, Dedon PC. Reactive species and DNA damage in chronic inflammation: Reconciling chemical mechanisms and biological fates. Int J Cancer. 2011; 128: 1999-2009.
24. Ambs S, Merriam WG, Bennett WP, Felley-Bosco E, Ogunfusika MO, Oser SM, et al. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res. 1998; 58: 334-341.
25. Min/+ mice by inhibiting nitric oxide production. Cancer Res. 2001; 61: 8357-8360.
26. Min/+ mice. Int J Cancer. 2007; 121: 506-513.
27. Agoff SN, Brentnall TA, Crispin DA, Taylor SL, Raaka S, Haggitt RC, et al. The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Am J Pathol. 2000; 157: 737-745.
28. Hao X, Bishop AE, Wallace M, Wang H, Willcocks TC, Maclouf J, et al. Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis. J Pathol. 1999; 187: 295-301.
29. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995; 55: 3785-3789.
30. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, et al. Genetic disruption of Ptgs-1, as well as of Ptgs-2, reduces intestinal tumorigenesis in Min Mice. Cancer Res. 2000; 60: 4705-4708.
31. Pugh S, Thomas GAO. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut. 1994; 35: 675-678.
32. Nakanishi M, Montrose DC, Clark P, Nambiar PR, Belinsky GS, Claffey KP, et al. Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res. 2008; 68: 3251-3259.
33. DuBois RN, Smalley WE. Cyclooxygenase, NSAIDs, and colorectal cancer. J Gastroenterol. 1996; 31: 898-906.
34. Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res. 1996; 56: 710-714.
35. Min mouse by piroxicam: kinetics, strain effects, and resistance to chemosuppression. Carcinogenesis. 1999; 20: 51-58.
36. Langenbach R, Loftin CD, Lee C, Tiano H. Cyclooxygenase-deficient mice. Ann N Y Acad Sci. 1999; 889: 52-61.
37. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007; 369: 1603-1613.
38. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010; 376: 1741-1750.
39. Dubé C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, et al. The use of aspirin for primary prevention of colorectal cancer: A systematic review prepared for the U.S. preventive services task force. Ann Intern Med. 2007; 146: 365-375.
40. Grau MV, Sandler RS, McKeown-Eyssen G, Bresalier RS, Haile RW, Barry EL, et al. Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: Observational follow-up of a randomized study. J Natl Cancer Inst. 2009; 101: 267-276.
41. Cooper K, Squires H, Carroll C, Papaioannou D, Booth A, Logan RF, et al. Chemoprevention of colorectal cancer: Systematic review and economic evaluation. Health Technol Assess. 2010; 14: 201-206.
42. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Low-dose aspirin in the primary prevention of cancer. JAMA. 2005; 294: 47-55.
43. Knüpfer H, Preiss R. Serum interleukin-6 levels in colorectal cancer patients--a summary of published results. Int J Colorectal Dis. 2010; 25: 135-140.
44. Cacev T, Radosević S, Krizanac S, Kapitanović S. Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression. Carcinogenesis. 2008; 29: 1572-1580.
45. Csiszár A, Szentes T, Haraszti B, Balázs A, Petrányi GG, Pócsik É. The pattern of cytokine gene expression in human colorectal carcinoma. Pathol Oncol Res. 2004; 10: 109-116.
46. Cui G, Goll R, Olsen T, Eriksson Steigen S, Husebekk A, Vonen B, et al. Reduced expression of microenvironmental Th1 cytokines accompanies adenomas-carcinomas sequence of colorectum. Cancer Immunol Immunother. 2007; 56: 985-995.
47. Onizawa M, Nagaishi T, Kanai T, Nagano K-I, Oshima S, Nemoto Y, et al. Signaling pathway via TNF-α/NF-κB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. Am J Physiol Gastrointest Liver Physiol. 2009; 296: G850-G859.
48. Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, et al. Blocking TNF- α in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest. 2008; 118: 560-570.
49. Sakai H, Yamada Y, Shimizu M, Saito K, Moriwaki H, Hara A. Genetic ablation of Tnfα demonstrates no detectable suppressive effect on inflammation-related mouse colon tumorigenesis. Chem Biol Interact. 2010; 184: 423-430.
50. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009; 15: 103-113.
51. Baltgalvis KA, Berger FG, Pena MMO, Davis JM, Muga SJ, Carson JA. Interleukin-6 and cachexia in ApcMin/+ mice. Am J Physiol Regul Integr Comp Physiol. 2008; 294: R393-R401.
52. Kanneganti M, Mino-Kenudson M, Mizoguchi E. Animal models of colitis-associated carcinogenesis. J Biomed Biotechnol. 2011; doi:10.1155/2011/342637.
53. Huang EH, Park JC, Appelman H, Weinberg AD, Banerjee M, Logsdon CD, et al. Induction of inflammatory bowel disease accelerates adenoma formation in Min+/- mice. Surgery. 2006; 139: 782-788.
54. Kim SJ, Im YH, Markowitz SD, Bang YJ. Molecular mechanisms of inactivation of TGF-β receptors during carcinogenesis. Cytokine Growth Factor Rev. 2000; 11: 159-168.
55. Muñoz NM, Upton M, Rojas A, Washington MK, Lin L, Chytil A, et al. Transforming growth factor β receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation. Cancer Res. 2006; 66: 9837-9844.
56. Karin M. NF-κB and cancer: mechanisms and targets. Mol Carcinog. 2006; 45: 355-361.
57. Murano M, Maemura K, Hirata I, Toshina K, Nishikawa T, Hamamoto N, et al. Therapeutic effect of intracolonically administered nuclear factor κB (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis. Clin Exp Immunol. 2000; 120: 51-58.
58. MacMaster JF, Dambach DM, Lee DB, Berry KK, Qiu Y, Zusi F, et al. An inhibitor of IκB kinase, BMS-345541, blocks endothelial cell adhesion molecule expression and reduces the severity of dextran sulfate sodium-induced colitis in mice. Inflamm Res. 2003; 52: 508-511.
59. Shibata W, Maeda S, Hikiba Y, Yanai A, Ohmae T, Sakamoto K, et al. Cutting edge: The IκB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury in murine colitis. J Immunol. 2007; 179: 2681-2685.
60. Nenci A, Becker C, Wullaert A, Gareus R, van Loo G, Danese S, et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature. 2007; 446: 557-561.
61. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004; 118: 285-296.
62. Hayakawa Y, Maeda S, Nakagawa H, Hikiba Y, Shibata W, Sakamoto K, et al. Effectiveness of IκB kinase inhibitors in murine colitis-associated tumorigenesis. J Gastroenterol. 2009; 44: 935-943.
63. Sethi G, Sung B, Aggarwal BB. Nuclear factor-κB activation: From bench to bedside. Exp Biol Med. 2008; 233: 21-31.
64. Rajakangas J, Pajari AM, Misikangas M, Mutanen M. Nuclear factor κB is downregulated and correlates with p53 in the Min mouse mucosa during an accelerated tumor growth. Int J Cancer. 2006; 118: 279-283.
65. Lind DS, Hochwald SN, Malaty J, Rekkas S, Hebig P, Mishra G, et al. Nuclear factor-κB is upregulated in colorectal cancer. Surgery. 2001; 130: 363-369.
66. Yu LL, Yu HG, Yu JP, Luo HS, Xu XM, Li JH. Nuclear factor-κB p65 (RelA) transcription factor is constitutively activated in human colorectal carcinoma tissue. World J Gastroenterol. 2004; 10: 3255-3260.
67. Aranha MM, Borralho PM, Ravasco P, Moreira da Silva IB, Correia L, Fernandes A, et al. NF-κB and apoptosis in colorectal tumourigenesis. Eur J Clin Invest. 2007; 37: 416-424.
68. Charalambous MP, Lightfoot T, Speirs V, Horgan K, Gooderham NJ. Expression of COX-2, NF-κB-p65, NF-κB-p50 and IKKα in malignant and adjacent normal human colorectal tissue. Br J Cancer. 2009; 101: 106-115.
69. Horst D, Budczies J, Brabletz T, Kirchner T, Hlubek F. Invasion associated up-regulation of nuclear factor κB target genes in colorectal cancer. Cancer. 2009; 115: 4946-4958.
70. Andersen V, Christensen J, Overvad K, Tjønneland A, Vogel U. Polymorphisms in NFκB, PXR, LXR, and risk of colorectal cancer in a prospective study of Danes. BMC Cancer. 2010; 10: 484.
71. Song S, Chen D, Lu J, Liao J, Luo Y, Yang Z, et al. NFκB1 and NFκBIA polymorphisms are associated with increased risk for sporadic colorectal cancer in a southern Chinese population. PloS ONE. 2011; 6: e21726. doi:10.1371/journal.pone.0021726.
72. Hope ME, Hold GL, Kain R, El-Omar EM. Sporadic colorectal cancer--role of the commensal microbiota. FEMS Microbiol Lett. 2005; 244: 1-7.
73. Scanlan PD, Shanahan F, Clune Y, Collins JK, O'Sullivan GC, O'Riordan M, et al. Culture-independent analysis of the gut microbiota in colorectal cancer and polyposis. Environ Microbiol. 2008; 10: 789-798.
74. Onoue M, Kado S, Sakaitani Y, Uchida K, Morotomi M. Specific species of intestinal bacteria influence the induction of aberrant crypt foci by 1,2-dimethylhydrazine in rats. Cancer Lett. 1997; 113: 179-186.
75. Vannucci L, Stepankova R, Kozakova H, Fiserova A, Rossmann P, Tlaskalova-Hogenova H. Colorectal carcinogenesis in germ-free and conventionally reared rats: different intestinal environments affect the systemic immunity. Int J Oncol. 2008; 32: 609-617.
76. Sellin JH, Umar S, Xiao J, Morris AP. Increased β-catenin expression and nuclear translocation accompany cellular hyperproliferation in vivo. Cancer Res. 2001; 61: 2899-2906.
77. Franco AT, Israel DA, Washington MK, Krishna U, Fox JG, Rogers AB, et al. Activation of β-catenin by carcinogenic Helicobacter pylori. Proc Natl Acad Sci USA. 2005; 102: 10646-10651.
78. Sears CL. Enterotoxigenic Bacteroides fragilis: A rogue among symbiotes. Clin Microbiol Rev. 2009; 22: 349-369.
79. Sobhani I, Tap J, Roudot-Thoraval F, Roperch JP, Letulle S, Langella P, et al. Microbial dysbiosis in colorectal cancer (CRC) patients. PloS ONE. 2011; 6: e16393. doi:10.1371/journal.pone.0016393.
80. Barbosa T, Rescigno M. Host-bacteria interactions in the intestine: Homeostasis to chronic inflammation. WIREs Syst Biol Med. 2010; 2: 80-97.
81. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun. 2000; 68: 7010-7017.
82. Cario E. Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis. 2010; 16: 1583-1597.
83. Frolova L, Drastich P, Rossmann P, Klimesova K, Tlaskalova-Hogenova H. Expression of Toll-like receptor 2 (TLR2), TLR4, and CD14 in biopsy samples of patients with inflammatory bowel diseases: Upregulated expression of TLR2 in terminal ileum of patients with ulcerative colitis. J Histochem Cytochem. 2008; 56: 267-274.
84. Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, et al. Toll-like receptor-4 (TLR4) promotes the development of colitisassociated colorectal tumors. Gastroenterology. 2007; 133: 1869-1881.
85. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 2005; 65: 5009-5014.
86. Fukata M, Chen A, Klepper A, Krishnareddy S, Vamadevan AS, Thomas LS, et al. Cox-2 is regulated by toll-like receptor-4 (TLR4) signalling and is important for proliferation and apoptosis in response to intestinal mucosal injury. Gastroenterology. 2006; 131: 862-877.
87. Fukata M, Michelsen KS, Eri R, Thomas LS, Hu B, Lukasek K, et al. Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol. 2005; 288: G1055-G1065.
88. Heimesaat MM, Fischer A, Siegmund B, Kupz A, Niebergall J, Fuchs D, et al. Shift towards pro-inflammatory intestinal bacteria aggravates acute murine colitis via Toll-like receptors 2 and 4. PloS ONE. 2007; 2: e662. doi:10.1371/journal.pone.0000662.
89. Rhee SH, Im E, Pothoulakis C. Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology. 2008; 135: 518-528.
90. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science. 2007; 317: 124-127.
91. Chen GY, Shaw MH, Redondo G, Núñez G. The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. Cancer Res. 2008; 68: 10060-10067.
92. Zaki MH, Vogel P, Body-Malapel M, Lamkanfi M, Kanneganti T-D. IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J Immunol. 2010; 185: 4912-4920.
93. Hu B, Elinav E, Huber S, Booth CJ, Strowig T, Jin C, et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci USA. 2010; 107: 21635-21640.
94. Chen GY, Liu M, Wang F, Bertin J, Núñez G. A functional role for nlrp6 in intestinal inflammation and tumorigenesis. J Immunol. 2011; 186: 7187-7194.